Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of doravirine/islatravir vs bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 infection
2022-502099-22-01Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of doravirine + islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, Percentage of participants experiencing ≥1 adverse event through Week 48 and 1 more. Planned start Mar 2024; status: authorised.
02
Drugs
doravirine + islatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2022-502099-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502099-22-01.